|
1
|
Tontini GE, Vecchi M, Pastorelli L,
Neurath MF and Neumann H: Differential diagnosis in inflammatory
bowel disease colitis: State of the art and future perspectives.
World J Gastroenterol. 21:21–46. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vavricka SR, Schoepfer A, Scharl M,
Lakatos PL, Navarini A and Rogler G: Extraintestinal manifestations
of inflammatory bowel disease. Inflamm Bowel Dis. 21:1982–1992.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Vavricka SR, Rogler G, Gantenbein C,
Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E,
Fournier N, Straumann A, et al: Chronological order of appearance
of extraintestinal manifestations relative to the time of IBD
diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm
Bowel Dis. 21:1794–1800. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Monsén U, Sorstad J, Hellers G and
Johansson C: Extracolonic diagnoses in ulcerative colitis: An
epidemiological study. Am J Gastroenterol. 85:711–716.
1990.PubMed/NCBI
|
|
5
|
Das KM: Relationship of extraintestinal
involvements in inflammatory bowel disease: New insights into
autoimmune pathogenesis. Dig Dis Sci. 44:1–13. 1999.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vavricka SR, Brun L, Ballabeni P, Pittet
V, Prinz Vavricka BM, Zeitz J, Rogler G and Schoepfer AM: Frequency
and risk factors for extraintestinal manifestations in the Swiss
inflammatory bowel disease cohort. Am J Gastroenterol. 106:110–119.
2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bernstein CN, Blanchard JF, Rawsthorne P
and Yu N: The prevalence of extraintestinal diseases in
inflammatory bowel disease: A population-based study. Am J
Gastroenterol. 96:1116–1122. 2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Greuter T, Navarini A and Vavricka SR:
Skin manifestations of inflammatory bowel disease. Clin Rev Allergy
Immunol. 53:413–427. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hagen JW, Swoger JM and Grandinetti LM:
Cutaneous manifestations of Crohn disease. Dermatol Clin.
33:417–431. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xavier RJ and Podolsky DK: Unravelling the
pathogenesis of inflammatory bowel disease. Nature. 448:427–434.
2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rankin GB, Watts HD, Melnyk CS and Kelley
ML Jr: National Cooperative Crohn's Disease Study: Extraintestinal
manifestations and perianal complications. Gastroenterology.
77:914–920. 1979.PubMed/NCBI
|
|
12
|
Trash B, Patel M, Shah KR, Boland CR and
Menter A: Cutaneous manifestations of gastrointestinal disease Part
II. J Am Acad Dermatol. 68:211.e1–33. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Muhvić-Urek M, Tomac-Stojmenović M and
Mijandrušić-Sinčić B: Oral pathology in inflammatory bowel disease.
World J Gastroenterol. 22:5655–5667. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lebwohl M, Fleischmajer R, Janowitz H,
Present D and Prioleau PG: Metastatic Crohn's disease. J Am Acad
Dermatol. 10:33–38. 1984.
|
|
15
|
Hawryluk EB, Izikson L and English JC III:
Non-infectious granulomatous diseases of the skin and their
associated systemic diseases: An evidence-based update to important
clinical questions. Am J Clin Dermatol. 11:171–181. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Guest GD and Fink RL: Metastatic Crohn's
disease: Case report of an unusual variant and review of the
literature. Dis Colon Rectum. 43:1764–1766. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rahvar M and Kerstetter J: Cutaneous
manifestation of gastrointestinal disease. J Gastrointest Oncol. 7
(Suppl 1):S44–S54. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chowaniec M, Starba A and Wiland P:
Erythema nodosum - review of the literature. Reumatologia.
54:79–82. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Farhi D, Cosnes J, Zizi N, Chosidow O,
Seksik P, Beaugerie L, Aractingi S and Khosrotehrani K:
Significance of erythema nodosum and pyoderma gangrenosum in
inflammatory bowel diseases: A cohort study of 2402 patients.
Medicine (Baltimore). 87:281–293. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Apgar JT: Newer aspects of inflammatory
bowel disease and its cutaneous manifestations: A selective review.
Semin Dermatol. 10:138–147. 1991.PubMed/NCBI
|
|
21
|
Harbord M, Annese V, Vavricka SR, Allez M,
Barreiro-de Acosta M, Boberg KM, Burisch J, De Vos M, De Vries AM,
Dick AD, et al: European Crohn's and Colitis Organisation: The
first European evidence-based consensus on extra-intestinal
manifestations in inflammatory bowel disease. J Crohn's Colitis.
10:239–254. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Callen JP: Pyoderma gangrenosum. Lancet.
351:581–585. 1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Menachem Y and Gotsman I: Clinical
manifestations of pyoderma gangrenosum associated with inflammatory
bowel disease. Isr Med Assoc J. 6:88–90. 2004.PubMed/NCBI
|
|
24
|
Polcz M, Gu J and Florin T: Pyoderma
gangrenosum in inflammatory bowel disease: The experience at Mater
Health Services' Adult Hospital 1998-2009. J Crohn's Colitis.
5:148–151. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rothfuss KS, Stange EF and Herrlinger KR:
Extraintestinal manifestations and complications in inflammatory
bowel diseases. World J Gastroenterol. 12:4819–4831.
2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cosgarea R, Senilă SC, Badea R and
Ungureanu L: Pyoderma gangrenosum with spleen involvement. Review
of the literature and case report. J Dermatol Case Rep. 10:26–31.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wollina U: Pyoderma gangrenosum - a
systemic disease? Clin Dermatol. 33:527–530. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fonder MA, Cummins DL, Ehst BD, Anhalt GJ
and Meyerle JH: Adalimumab therapy for recalcitrant pyoderma
gangrenosum. J Burns Wounds. 5(e8)2006.PubMed/NCBI
|
|
29
|
Femiano F, Lanza A, Buonaiuto C, Perillo
L, Dell'Ermo A and Cirillo N: Pyostomatitis vegetans: A review of
the literature. Med Oral Patol Oral Cir Bucal. 14:E114–E117.
2009.PubMed/NCBI
|
|
30
|
Hindryckx P, Novak G, Costanzo A and
Danese S: Disease-related and drug-induced skin manifestations in
inflammatory bowel disease. Expert Rev Gastroenterol Hepatol.
11:203–214. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Marzano AV, Borghi A, Wallach D and Cugno
M: A comprehensive review of neutrophilic diseases. Clin Rev
Allergy Immunol. 54:114–130. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Travis S, Innes N, Davies MG, Daneshmend T
and Hughes S: The South West Gastroenterology Group: Sweet's
syndrome: An unusual cutaneous feature of Crohn's disease or
ulcerative colitis. Eur J Gastroenterol Hepatol. 9:715–720.
1997.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ytting H, Vind I, Bang D and Munkholm P:
Sweet's syndrome - an extraintestinal manifestation in inflammatory
bowel disease. Digestion. 72:195–200. 2005.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ardizzone S, Puttini PS, Cassinotti A and
Porro GB: Extraintestinal manifestations of inflammatory bowel
disease. Dig Liver Dis. 40 (Suppl 2):S253–S259. 2008.
|
|
35
|
El-Azhary RA, Brunner KL and Gibson LE:
Sweet syndrome as a manifestation of azathioprine hypersensitivity.
Mayo Clin Proc. 83:1026–1030. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Choonhakarn C and Chaowattanapanit S:
Azathioprine-induced Sweet's syndrome and published work review. J
Dermatol. 40:267–271. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Diaz-Perez JL, Schroeter AL and Winkelmann
RK: Cutaneous periarteritis nodosa: Immunofluorescence studies.
Arch Dermatol. 116:56–58. 1980.PubMed/NCBI
|
|
38
|
Borrie P: Cutaneous polyarteritis nodosa.
Br J Dermatol. 87:87–95. 1972.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ozen S: The changing face of polyarteritis
nodosa and necrotizing vasculitis. Nat Rev Rheumatol. 13:381–386.
2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Akbulut S, Ozaslan E, Topal F, Albayrak L,
Kayhan B and Efe C: Ulcerative colitis presenting as
leukocytoclastic vasculitis of skin. World J Gastroenterol.
14:2448–2450. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zlatanic J, Fleisher M, Sasson M, Kim P
and Korelitz BI: Crohn's disease and acute leukocytoclastic
vasculitis of skin. Am J Gastroenterol. 91:2410–2413.
1996.PubMed/NCBI
|
|
42
|
Iannone F, Scioscia C, Musio A, Piscitelli
D and Lapadula G: Leucocytoclastic vasculitis as onset symptom of
ulcerative colitis. Ann Rheum Dis. 62:785–786. 2003.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lentz SR: Thrombosis in the setting of
obesity or inflammatory bowel disease. Blood. 128:2388–2394.
2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Nguyen GC, Bernstein CN, Bitton A, Chan
AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD,
Carrier M, et al: Consensus statements on the risk, prevention, and
treatment of venous thromboembolism in inflammatory bowel disease:
Canadian Association of Gastroenterology. Gastroenterology.
146:835–848.e6. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Grainge MJ, West J and Card TR: Venous
thromboembolism during active disease and remission in inflammatory
bowel disease: A cohort study. Lancet. 375:657–663. 2010.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zitomersky NL, Verhave M and Trenor CC
III: Thrombosis and inflammatory bowel disease: A call for improved
awareness and prevention. Inflamm Bowel Dis. 17:458–470.
2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Reddy H, Shipman AR and Wojnarowska F:
Epidermolysis bullosa acquisita and inflammatory bowel disease: A
review of the literature. Clin Exp Dermatol. 38:225–229.
2013.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kim M, Choi KH, Hwang SW, Lee YB, Park HJ
and Bae JM: Inflammatory bowel disease is associated with an
increased risk of inflammatory skin diseases: A population-based
cross-sectional study. J Am Acad Dermatol. 76:40–48.
2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Shapiro JM, Subedi S and LeLeiko NS:
Inflammatory bowel disease. Pediatr Rev. 37:337–347.
2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Segaert S and Hermans C: Clinical signs,
pathophysiology and management of cutaneous side effects of
anti-tumor necrosis factor agents. Am J Clin Dermatol. 18:771–787.
2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Cleynen I, Van Moerkercke W, Billiet T,
Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V,
Ferrante M, Noman M, Assche GV, et al: Characteristics of skin
lesions associated with anti-tumor necrosis factor therapy in
patients with inflammatory bowel disease: A cohort study. Ann
Intern Med. 164:10–22. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Guttman-Yassky E, Ungar B, Noda S, Suprun
M, Shroff A, Dutt R, Khattri S, Min M, Mansouri Y, Zheng X, et al:
Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine
antagonism. J Allergy Clin Immunol. 137:301–304. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Peyrin-Biroulet L, Van Assche G,
Gómez-Ulloa D, García-Álvarez L, Lara N, Black CM and Kachroo S:
Systematic review of tumor necrosis factor antagonists in
extraintestinal manifestations in inflammatory bowel disease. Clin
Gastroenterol Hepatol. 15:25–36.e27. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Esmailzadeh A, Yousefi P, Farhi D,
Bachmeyer C, Cosnes J, Berenbaum F, Duriez P, Aractingi S and
Khosrotehrani K: Predictive factors of eczema-like eruptions among
patients without cutaneous psoriasis receiving infliximab: A cohort
study of 92 patients. Dermatology. 219:263–267. 2009.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Lee HH, Song IH, Friedrich M, Gauliard A,
Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, et
al: Cutaneous side-effects in patients with rheumatic diseases
during application of tumour necrosis factor-alpha antagonists. Br
J Dermatol. 156:486–491. 2007.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Flendrie M, Vissers WH, Creemers MC, de
Jong EM, van de Kerkhof PC and van Riel PL: Dermatological
conditions during TNF-alpha-blocking therapy in patients with
rheumatoid arthritis: a prospective study. Arthritis Res Ther.
7:R666–R676. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
57
|
Fulchiero GJ Jr, Salvaggio H, Drabick JJ,
Staveley-O'Carroll K, Billingsley EM, Marks JG and Helm KF:
Eruptive latent metastatic melanomas after initiation of antitumor
necrosis factor therapies. J Am Acad Dermatol. 56 (Suppl
5):S65–S67. 2007.PubMed/NCBI View Article : Google Scholar
|
